IPM Take
The sharp signal is that HIV prevention now has a tool that could overcome some of the real-world barriers that daily oral PrEP never fully solved: stigma, adherence, privacy and repeated pharmacy access. But a six-monthly injection only changes the epidemic if supply, eligibility and delivery are designed around the people most at risk. Lenacapavir is not just a biomedical breakthrough. It is a test of whether global health can move faster this time.
Executive Summary
On 14 April 2026, the Global Fund and the United States announced an expanded commitment to scale up long-acting injectable lenacapavir for HIV PrEP, aiming to reach an additional 1 million people over three years and bringing the total joint ambition to 3 million people by 2028. Initial deliveries had reached nine African countries, while support was extended to 12 additional countries across Africa, Asia-Pacific, Latin America and the Caribbean, and the Middle East and North Africa. UNAIDS welcomed the rollout but stressed that at least 20 million people need access to antiretroviral-based prevention options by 2030.
Why it matters
- Public authorities: Need to define priority populations, delivery sites, injection schedules, HIV testing and follow-up systems
- Patients / advocates: Should track whether access reaches people facing stigma, adherence barriers and limited access to daily oral PrEP.
- Payers / funders: Must prepare for supply constraints, financing sustainability, generic access and long-term integration into HIV prevention programmes.
Before lenacapavir, HIV prevention relied heavily on daily oral PrEP, condoms and other prevention tools. These remain important, but daily prevention is difficult for many people because of stigma, disclosure risk, adherence challenges and inconsistent access.
What has changed is the arrival of a twice-yearly injectable prevention option with strong clinical trial performance and a fast access push for lower-income settings. The Global Fund describes lenacapavir as a long-acting injectable administered twice a year that showed near 100% effectiveness in clinical trials. UNAIDS uses more cautious wording, stating that lenacapavir has shown to be at least 96% effective in preventing HIV.
The implementation question is no longer only whether the product works. It is who receives the first limited supply, how countries prioritise high-risk populations, how clinics deliver injections every six months, how HIV testing is built into continuation and how generic supply is accelerated. WHO recommends long-acting injectable lenacapavir as an additional HIV prevention choice as part of combination prevention approaches, and also emphasises flexible HIV testing approaches so testing does not become a barrier to starting or continuing injectable PrEP.
For IPM, lenacapavir is precision public health: the right prevention tool, delivered to people whose risk and access barriers make daily PrEP insufficient. The challenge is to make that precision equitable, not only biologically effective.
